MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality
| Autor: | Oliveira, Antonio Talvane Torres de [UNIFESP], Matos, Delcio [UNIFESP], Logullo, Angela Flavia [UNIFESP], Silva, Sandra Regina Morini da [UNIFESP], Artigiani Neto, Ricardo [UNIFESP], Longat Filho, Adhemar, Saad, Sarhan Sydney [UNIFESP] |
|---|---|
| Přispěvatelé: | Barretos Canc Hosp, Universidade Federal de São Paulo (UNIFESP), Univ Minho, Universidade de São Paulo (USP), Universidade do Minho |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Survival Carcinogenesis Medicina Básica [Ciências Médicas] Adenocarcinoma survival Proto-Oncogene Proteins Biomarkers Tumor Humans Receptors Growth Factor Aged Neoplasm Staging Aged 80 and over Science & Technology Middle Aged Proto-Oncogene Proteins c-met Prognosis Immunohistochemistry Colorectal carcinoma Ciências Médicas::Medicina Básica immunohistochemistry MET prognosis Colorectal Neoplasms carcinogenesis |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP Repositório Institucional da UNIFESP Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
| Popis: | The aim of the present study was to evaluate by immunohistochemistry the prognostic meaning of the tumor marker MET (hepatocyte growth factor) in patients submitted to surgical resection due to primary colorectal adenocarcinoma. Patients and Methods: A retrospective study was carried out that included 286 consecutive patients with colorectal adenocarcinoma, submitted to surgical resection at Barretos Cancer Hospital, from 1993 to 2002. The histopathological expression of the MET tumor marker was evaluated using an anti-protein monoclonal antibody against MET by the streptavidin-biotin-peroxidase technique. The expression of the tumor marker was semi-quantitative, and the slide samples were independently analyzed by three pathologists unaware of patient clinical and histopathological data. Results: The tumor marker expression was positive in 236 (79%) out of a total of 286 patients. This expression was statistically significantly different between stages I and IV (p=0.004), for overall survival (p=0.009), and for cancer-related mortality rates (p=0.022). However, no association between the tumor marker and recurrence (p=0.89) or disease-free interval (p=0.91) was observed. Conclusion: MET has shown significant expression at advanced stages of the disease, as well as for overall survival and cancer-related mortality rates demonstrating to be a valuable marker for poor prognosis in colorectal cancer patients. Barretos Canc Hosp, Pio Fdn 12, Dept Surg, Sao Paulo, Brazil Barretos Canc Hosp, Pio Fdn 12, Dept Pathol, Sao Paulo, Brazil Univ Fed Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil Univ Fed Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal Univ Sao Paulo, Sch Med, Dept Pathol, Lab Med Invest LIM 14, Sao Paulo, Brazil Univ Fed Sao Paulo, Dept Gastroenterol, Sch Med, Sao Paulo, Brazil Univ Fed Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil Web of Science |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|